StockNews.com Begins Coverage on Evogene (NASDAQ:EVGN)

StockNews.com started coverage on shares of Evogene (NASDAQ:EVGN) in a research note released on Saturday. The brokerage issued a sell rating on the biotechnology company’s stock.

Evogene Stock Performance

Shares of EVGN opened at $0.64 on Friday. The business’s fifty day moving average price is $0.68 and its two-hundred day moving average price is $0.76. The firm has a market capitalization of $26.38 million, a price-to-earnings ratio of -1.39 and a beta of 1.40. Evogene has a 52 week low of $0.45 and a 52 week high of $1.20.

Evogene (NASDAQ:EVGN) last announced its quarterly earnings data on Thursday, May 23rd. The biotechnology company reported ($0.08) earnings per share for the quarter. Evogene had a negative return on equity of 70.96% and a negative net margin of 233.66%. The firm had revenue of $4.19 million for the quarter.

Hedge Funds Weigh In On Evogene

An institutional investor recently raised its stake in Evogene stock. BNP Paribas Financial Markets grew its position in shares of Evogene Ltd. (NASDAQ:EVGN) by 30.8% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 91,400 shares of the biotechnology company’s stock after acquiring an additional 21,500 shares during the quarter. BNP Paribas Financial Markets owned 0.22% of Evogene worth $69,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 10.40% of the company’s stock.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.